ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts...
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and...
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2...
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.82 | 11.1869031378 | 7.33 | 8.16 | 7.17 | 469554 | 7.6011089 | CS |
4 | 0.12 | 1.49439601494 | 8.03 | 8.57 | 7.09 | 525721 | 7.62697581 | CS |
12 | -0.92 | -10.1433296582 | 9.07 | 10.21 | 7.09 | 573435 | 8.4769151 | CS |
26 | -6.44 | -44.1398217958 | 14.59 | 18.13 | 7.09 | 540066 | 11.14029336 | CS |
52 | -3.4 | -29.4372294372 | 11.55 | 18.75 | 7.09 | 448463 | 12.13741441 | CS |
156 | -43.75 | -84.2967244701 | 51.9 | 52.43 | 7.09 | 411556 | 17.65527674 | CS |
260 | -11.55 | -58.6294416244 | 19.7 | 52.43 | 7.09 | 363084 | 20.32965149 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions